NR3C2 and type 2 diabetes mellitus: The addition of MR antagonists has reduced albuminuria in people with T2DM and kidney disease and people with non-diabetic chronic kidney disease (CKD) (Mehdi et al., 2009; Vukadinovic et al., 2017).